500 RIVER RIDGE DRIVE, NORWOOD, MA
Reports Q2 2026 Financial Results and Provides a Corporate Update
Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer
Investor Presentation
Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
Reports Q1 2026 Financial Results and Provides a Corporate Update
Executive Appointments - Yuval Cohen and Sean Moran Employment Agreements
Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload
Registration of Securities under Section 12(g)